Material matter: Korean phase 3 trial protocol amendment filed for CTP44, a Darzalex biosimilar
DART
Celltrion, Inc.
Filed Aug 3, 2026 KST · Filing
· receipt 20260803800514
kstock has not written this one up.
The title above is a translation of the Korean form name; the filing itself is on DART, in
Korean.
Read the original on DART ↗Korean. DART is Korea's electronic disclosure system, run by the Financial Supervisory
Service — the filing equivalent of EDGAR.
Korean form name: 투자판단관련주요경영사항 (CTP44(다잘렉스 바이오시밀러) 한국 임상 3상 시험계획 변경신청)